Skip to main content
Erschienen in: Esophagus 2/2017

Open Access 03.01.2017 | Original Article

Re-evaluation of the role of thoracoscopic esophagectomy as a Japanese-style radical surgery

verfasst von: Harushi Udagawa, Masaki Ueno, Shusuke Haruta, Tsuyoshi Tanaka, Aya Mizuno, Yu Ohkura

Erschienen in: Esophagus | Ausgabe 2/2017

download
DOWNLOAD
print
DRUCKEN
insite
SUCHEN

Abstract

Purpose

To investigate the value of thoracoscopic surgery in radical esophagectomy with three-field lymphadenectomy.

Materials and method

The subjects were 329 consecutive patients who, without preoperative chemoradiotherapy, underwent R0 radical esophagectomy with three-field lymphadenectomy for thoracic squamous cell esophageal cancers during 1998–2013. Open thoracotomy was applied in 212 (O), and thoracoscopic surgery in 117 (V). Survivals according to TNM Stages and Efficacy index (EI) were analyzed.

Results

Hospital death rates of O/V were 1.9/0%. The survivals of V according to TNM Stages had significantly better prognosis in TNM6th cStage III and showed not worse prognosis in general. In the analysis using Cox proportional hazards model, “V or O” was a significant prognostic factor indicating better prognosis of V. More bilateral paratracheal lymph nodes along the recurrent laryngeal nerves tended to be classified as mediastinal instead of cervical in V. Efficacy index of mediastinal paratracheal nodes was higher in V than in O, while cervical lymphadenectomy maintained high EI.

Discussion and conclusion

Though our series have limitations of retrospective study and substantial bias, the feasibility and safety of thoracoscopic esophagectomy with three-field lymphadenectomy was shown. Higher paratracheal lymph nodes along the recurrent laryngeal nerves could be dissected from the mediastinal side in V group. Thoracoscopic esophagectomy, which is regarded as minimally invasive surgery in other countries, is being accepted in Japan mainly in the expectation of more thorough and meticulous lymphadenectomy. At the same time, the dissection range is continuously re-evaluated for safer surgery maintaining radicality.

Introduction

In basic Japanese concept of multimodal treatment of esophageal cancer, radical surgery plays the main role in loco-regional control, and wide range of thorough lymphadenectomy is believed to be mandatory. The three-field lymphadenectomy is accepted as the standard procedure for this purpose [1]. On the other hand, thoracoscopic esophagectomy is rapidly prevailing in Japan. About 30% of esophagectomy in Japan is performed as thoracoscopic surgery [2, 3]. Thoracoscopic esophagectomy is generally regarded and accepted as a minimally invasive surgery in western countries [4, 5]. However, most of thoracoscopic surgeons in Japan try to perform thoracoscopic esophagectomy as radical as their own open surgery and think that thoracoscopic esophagectomy is even advantageous in accomplishing meticulous radical surgery [6, 7]. The purpose of this study was to clarify whether such high radicality was maintained and whether the value of three-field lymphadenectomy had been changed with the introduction of thoracoscopic surgery.

Materials and method

A total of 419 consecutive patients who underwent curative radical esophagectomy with three-field lymphadenectomy for thoracic squamous cell esophageal cancers during 1998–2013 were first extracted for this study. Ninety patients who underwent neoadjuvant chemoradiotherapy (NACRT) were excluded because NACRT, which was applied to patients with bulky T3 or suspicious T4 tumors including metastatic lymph nodes, seemed to be the largest bias between the groups of patients with open surgery (NACRT: 85) and thoracoscopic surgery (NACRT: 5). Consequently, subjects of the study were 329 patients, 201 in open thoracotomy group (O group), and 117 in video-assisted (=thoracoscopic) surgery group (V group). The open esophagectomy with three-field lymphadenectomy was performed as had been described by Akiyama [8]. The video-assisted esophagectomy was done with essentially similar technique to what had been described by Osugi [9]. The video-assisted esophagectomy was started in September of 2006. Survivals according to TNM Stages and Efficacy index [10] (EI: metastatic rate % × 5-y survival% × 1/100) were analyzed. The characteristics of the 329 subjects are listed in Table 1. The sixth edition of TNM classification [11] was applied in clinical TNM evaluation because number of clinically positive lymph nodes in preoperative staging was not available in patients before 2009. Pathological TNM staging was done according to the seventh edition of TNM [12]. The analysis on individual lymph node stations was done according to the latest classification by Japan Esophageal Society [13].
Table 1
Characteristics of the subjects
Subjects
329 patients
 
Interval
1998–2013
Diagnosis
Thoracic esophageal squamous cell carcinoma
 
Neoadjuvant Tx.
None or chemotherapy (CRT excluded)
 
Operation
Three-field lymphadenectomy, R0 resection
 
Group
O (open)
V (video-assisted)
P value
Number
212
117
 
Age
62.3 ± 8.5
62.4 ± 8.3
.937**
Sex
 Male/female
190/22
103/14
.713
Location
 U/M/L
29/127/56
23/66/28
.360*
Preoperative treatment
 None/Chemo
166/46
49/68
<.001
cT (TNM6th)
 1a/1b/2/3/4
3/68/42/95/4
5/38/39/34/1
.009*
cN (TNM6th)
 0/1
62/150
43/74
.175
cM (TNM6th)
 0/1a/1b
175/8/29
107/2/8
.087*
cSt (TNM6th)
 I/IIA/IIB/III/IVA/IVB
39/23/42/71/8/29
27/16/40/24/2/8
.006*
pT (TNM7th)
 0/1a/1b/2/3/4a/4b
1/15/71/20/100/5/0
0/15/46/25/31/0/0
.001*
pN (TNM7th)
 0/1/2/3
79/62/43/28
41/46/24/6
.066*
pM (TNM7th)
 0/1
173/39
102/15
.216
pSt (TNM7th)
 IA/IB/IIA/IIB/IIIA/IIIB/IIIC/IV
41/10/26/30/31/22/13/39
19/9/10/30/25/7/2/15
.023*
Hospital death
4 (1.9%)
0
.301
In pT(TNM7th) column, ypT0 is listed as T0
In pSt(TNM7th) column, ypT0N0M0 is included in IA, and ypT0N1M0 is included in IB
Statistical significance * Pearson’s Chi-square test, ** t test, others Fisher’s exact test
Pearson’s Chi-square test, Fisher’s exact test, and t test were used for distributional and numerical comparison. The survival curves were estimated according to the Kaplan–Meier method, and overall survival distributions were compared by use of the log-rank test. Cox proportional hazards model, forward stepwise method by likelihood ratio with the condition of .05 for addition and .1 for deletion, was applied to investigate prognostic factors. IBM SPSS Statistics 23® was used for data analysis.

Results

Hospital death rates of O/V were 1.9/0% (Table 1). Survivals according to cTNM6th Stages at first presentation of the patients were not statistically different between the two groups except among cSt III patients where V group showed better survival (Table 2, upper). The backgrounds of the 2 groups in this stage are not the same. Preoperative treatment was significantly different (None/Chemo of O was 55/16, while that of V was 5/19.), though preoperative treatment was not a significant prognostic factor in univariate analysis (Table 3). There was no significantly different distribution in other factors (data not shown). V group tended to show better survival in almost every pTNM7th stage though without statistical significance (Table 2, middle). Table 2 shows that V group had better survival than O group in TNM7th pN0 patients, the similar tendency in pN1, but did not in pN2 and pN3.
Table 2
Five-year survival of O group and V group according to TNM factors
 
O (%)
V (%)
P (Log rank)
5y.s. (S.E.)
5y.s. (S.E.)
TNM6th cStage
 I
86.9 (5.5)
89.3 (7.5)
.594
 IIA
65.2 (9.9)
78.7 (11.0)
.409
 IIB
78.6 (6.3)
83.5 (6.9)
.370
 III
50.9 (6.0)
73.0 (10.5)
.026
 IVA
25.0 (15.3)
– (–)
.685
 IVB
64.4 (9.0)
70.0 (18.2)
.836
TNM7th pStage
 IA
92.9 (4.1)
100 (–)
.239
 IB
80.0 (12.6)
100 (–)
.194
 IIA
72.7 (8.8)
100 (–)
.081
 IIB
73.3 (8.1)
86.1 (7.7)
.266
 IIIA
67.0 (8.6)
61.8 (10.8)
.701
 IIIB
57.1 (10.8)
75.0 (21.7)
.290
 IIIC
27.7 (13.5)
0 (–)
.300
 IV
35.9 (7.7)
70.0 (12.8)
.125
TNM7th pN
 0
84.8 (4.1)
100 (–)
.011
 1
64.0 (6.1)
74.2 (8.0)
.083
 2
59.5 (7.6)
73.5 (9.4)
.179
 3
23.2 (8.2)
25.0 (20.4)
.796
Table 3
Results of univariate Cox regression model
Covariate
B
SE
P
HR
V/O
−.837
.261
.001
.433
Period (L/F)
−.336
.213
.116
.715
PreTx.
 CT/NO
.001
.208
.995
1.001
Location
  
.339
 
U/M
.161
.268
.548
1.175
L/M
.307
.210
.145
1.359
Age (+1)
.032
.012
.008
1.032
Sex(M/F)
.424
.347
.222
1.528
cT (TNM6th)
  
.000
 
T1a/T2
−1.141
1.020
.263
.320
T1b/T2
−.480
.279
.085
.619
T3/T2
.456
.235
.052
1.577
T4/T2
1.487
.614
.015
4.424
cN (TNM6th)
    
N1/N0
.749
.226
.001
2.114
cM (TNM6th)
  
.004
 
M1a/M0
1.207
.393
.002
3.343
M1b/M0
.417
.265
.116
1.517
pT (TNM7th) *1
  
.000
 
T1a/T2
−.500
.548
.362
.607
T1b/T2
−.119
.367
.745
.887
T3/T2
.841
.340
.013
2.320
T4a/T2
1.970
.550
.000
7.171
pN (TNM7th)
  
.000
 
N1/N0
.918
.274
.001
2.504
N2/N0
1.188
.289
.000
3.279
N3/N0
2.199
.301
.000
9.019
pM (TNM7th)
    
M1/M0
1.021
.210
.000
2.777
B regression coefficient, SE standard error, HR hazard ratio = Exp(B)
Period F operated before we introduced video-assisted esophagectomy
Period L operated after we introduced video-assisted esophagectomy
The bold values indicate that the factors are statistically significant in univariate analyses and will be included in the next multivariate analyses
* 1 One pT0 patient in O group after chemotherapy is excluded to maintain appropriate statistical analysis
Twelve clinicopathological factors were examined as univariates for Cox proportional hazard model and found to be statistically significant except preoperative treatment, period of operation, tumor location, and sex (Table 3). Therefore, we decided that 8 factors with statistical significances should be included in the multivariate analysis. Because cTNM6th factors and pTNM7th factors should have strong correlation, Cox proportional hazards model was applied to the data set of 5 patient characteristics including cTNM6th factors but excluding pTNM7th factors. This pointed out that V/O status, cT, cM, and age were significant prognostic factors (Table 4, upper). When the same analysis was done to the data set of 5 patient characteristics including pTNM7th information but excluding cTNM6th pointed out that V/O status, pT, pN, and age were significant prognostic factors (Table 4, lower).
Table 4
Covariates in the equation of the Cox regression model
Covariate
B
SE
P
HR
Study with cTNM6th factors
 V/O
−.788
.265
.003
.455
 cT6th
  
.000
 
 T1a/T2
−.904
1.021
.376
.405
 T1b/T2
−.577
.281
.041
.562
 T3/T2
.334
.239
.164
1.396
 T4/T2
1.445
.618
.019
4.240
 cM6th
  
.46
 
 M1a/M0
.986
.400
.013
2.690
 M1b/M0
.050
.273
.859
1.052
 Age (+1)
.036
.012
.003
1.036
Study with pTNM7th factors*1
 V/O
−.629
.269
.019
.533
 pT7th
  
.011
 
 T1a/T2
−.066
.562
.907
.936
 T1b/T2
−.162
.370
.662
.850
 T3/T2
.578
.345
.094
1.782
 T4a/T2
.939
.579
.105
2.557
 pN7th
  
.000
 
 N1/N0
.920
.281
.001
2.510
 N2/N0
1.062
.303
.000
2.891
 N3/N0
2.143
.334
.000
8.526
 Age (+1)
.052
.012
.000
1.053
B regression coefficient, SE standard error, HR hazard ratio = Exp(B)
* 1: One pT0 patient in O group after chemotherapy is excluded to maintain appropriate statistical analysis
Number of dissected mediastinal nodes was significantly less in V group (O/V: 42.4/36.0) (Table 5, upper). Evident decrease in number of dissected lymph nodes in the station 106pre, which had the least EI value of .30, was observed (Table 5, lower). The number of bilateral mediastinal paratracheal nodes dissected was a little more in V group, though not statistically significant, and the number of bilateral cervical paratracheal nodes was significantly less in V (Table 5, lower). The percentage of paratracheal recurrent nerve chain nodes dissected from the mediastinal side in both groups is shown in Table 6. The percentage was higher on both sides in V group.
Table 5
Average numbers of dissected lymph nodes in O group and V group
Field
O
V
P (t test)
 Cervical
45.2 ± 16.2
42.9 ± 14.9
.189
 Mediastinal
42.4 ± 13.4
36.0 ± 12.3
<.001.
 Abdominal
29.1 ± 11.6
29.2 ± 11.6
.973
 3 fields
116.6 ± 28.8
108.0 ± 28.4
.010
Station
O
V
P
 106pre
6.1 ± 5.1
2.4 ± 2.8
<.001.
 101(R + L)
6.3 ± 4.0
5.3 ± 4.1
.033
 106rec(R + L)
9.9 ± 4.9
10.9 ± 5.6
.098
Table 6
Percentage of paratracheal lymph nodes dissected from the mediastinal side in O group and V group
Side
O (%)
V (%)
P (t test)
Right
58.5 ± 26.5
66.4 ± 25.1
.009
Left
63.8 ± 23.8
69.9 ± 23.1
.024
Bilateral
61.2 ± 19.8
67.8 ± 17.4
.003
Percentage of paratracheal lymph nodes dissected from the mediastinal side = number of 106rec nodes/(number of 106rec nodes + number of 101 nodes)
EI value of mediastinal paratracheal node station (106rec) was higher in V than in O. This was more evident on the left side (Table 7). The EI’s in both O and V groups for cervical, mediastinal, and abdominal lymphadenectomy were all very high, and no decrease in EI of cervical lymphadenectomy from O group to V group was observed (Table 8).
Table 7
EI’s of paratracheal (recurrent nerve chain) lymph node stations in O group and V group
Station
O or V
Met. r (%)
5-y s (%)
Efficacy index
101R
O
10.4
P = .031*
45.0
4.7
V
3.4
66.7
2.3
106recR
O
22.2
51.1
11.3
V
22.2
62.2
13.8
101L
O
6.6
50.0
3.3
V
5.1
83.3
4.2
106recL
O
10.4
P = .005*
52.5
5.5
V
22.2
71.5
15.8
* Fisher’s exact test
Table 8
EI’s of the three fields in O group and V group
Field
O or V
Met. r (%)
5-y s (%)
Efficacy index
Cervical
O
17.1
67.3
11.5
V
25.5
46.2
11.8
Mediastinal
O
47.6
51.5
24.5
V
52.1
67.5
35.2
Abdominal
O
38.2
P = .021*
46.6
17.8
V
25.6
67.4
17.3
* Fisher’s exact test

Discussion

Thoracoscopic esophagectomy, which is regarded as minimally invasive surgery in other countries, is being accepted in Japan very rapidly. According to the NCD report, about 30% of all esophagectomies performed in Japan in 2011 were done as video-assisted surgery. However, most Japanese surgeons performing video-assisted esophagectomy have the impression that the largest advantage of video-assisted esophagectomy is not its less invasiveness but the expectation of more thorough and meticulous lymphadenectomy. In our series, most of the analyses on prognosis showed tendency of improvement with video-assisted surgery. Taking the large bias of this study design into account, we feel at least we can conclude that the introduction of video-assisted surgery has not worsened the prognosis of our radical esophagectomy.
Bilateral paratracheal lymph nodes, which are also known as recurrent nerve chain nodes, are most important nodes to be dissected in radical esophagectomy for thoracic esophageal cancer. They are uninterruptedly located from the mediastinum to the cervical area. Our data showed that more paratracheal lymph nodes tend to be dissected from mediastinal side and fewer nodes were dissected from the cervical side in thoracoscopic esophagectomy. Consequently, EI’s of mediastinal paratracheal lymph node stations are higher in V group than in O group. The large increase in EI of the station 106recL from O to V might show not only the fact that more 106recL nodes including nodes in more cervical location can be dissected but also that more complete lymph node dissection of this station can be achieved in thoracoscopic surgery.
Although more nodes in cervical paratracheal station (101) can be dissected from the mediastinal side as 106rec in thoracoscopic esophagectomy, high EI value of cervical lymph node dissection is still maintained because of better 5-year survival of cervical node-positive patients in V group. It might mean that the combination of video-assisted mediastinal dissection + cervical lymphadenectomy be superior to the combination of conventional open mediastinal dissection + cervical lymphadenectomy in terms of completeness. At least we can say that three-field lymphadenectomy remains as the standard operative procedure even in the era of video-assisted surgery and multimodal treatment.
Because this study is a retrospective study, it should contain biases. The largest limitations are that V group was operated later than 2005 and that the distribution of clinical and pathological factors of the patients in both groups was different. The latter can be adjusted to some extent by stratifying patients according to these clinical and pathological factors. However, the former bias cannot be adjusted. We are looking forward to the coming results of JCOG1409, the phase III study among thoracoscopic esophagectomy and open esophagectomy.
Neoadjuvant chemoradiotherapy followed by surgery for resectable advanced thoracic esophageal cancer is widely accepted in all over the world. On the other hand, preoperative chemotherapy followed by surgery is regarded as standard in Japan. This strategy has yielded very good prognostic result as shown here. In this study, patients with NACRT were excluded because it was strongly associated with advanced T-stage, poorer prognosis, and open surgery. There is no direct evidence to compare NACRT and neoadjuvant chemotherapy particularly when the surgery includes Japanese-style extended lymphadenectomy. Japan Esophageal Oncology Group is executing a three-armed randomized controlled trial, JCOG1109 [14], to give answer to this question.

Conclusion

Japanese-style three-field lymphadenectomy pursuing best loco-regional control by surgery is feasibly and safely performed as thoracoscopic surgery. Thoracoscopic esophagectomy, which is regarded as minimally invasive surgery in other countries, has ability to realize more thorough and radical lymphadenectomy. This phenomenon was observed in the area along the recurrent laryngeal nerves. This increased radicality seems to improve long-term survival of the patients operated thoracoscopically. However, clear evidence of superiority of thoracoscopic surgery to conventional open surgery cannot be obtained until a phase III trial on this issue such as JCOG 1409 becomes available.

Compliance with ethical standards

Ethical Statement

We authors of this manuscript, “Re-evaluation of the role of thoracoscopic esophagectomy as a Japanese-style radical surgery” declare that our work conforms to the guidelines set forth in the Helsinki Declaration of 1975, as revised in 2000 and 2008, concerning Human and Animal Rights and that we followed out policy concerning Informed Consent as shown on Springer.com. (http://​www.​springer.​com/​gp/​authors-editors/​journal-author/​journal-author-helpdesk/​before-you-start).

Conflict of interest

There are no financial or other relations that could lead to a conflict of interest.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://​creativecommons.​org/​licenses/​by/​4.​0/​), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Unsere Produktempfehlungen

e.Med Interdisziplinär

Kombi-Abonnement

Für Ihren Erfolg in Klinik und Praxis - Die beste Hilfe in Ihrem Arbeitsalltag

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de.

e.Med Innere Medizin

Kombi-Abonnement

Mit e.Med Innere Medizin erhalten Sie Zugang zu CME-Fortbildungen des Fachgebietes Innere Medizin, den Premium-Inhalten der internistischen Fachzeitschriften, inklusive einer gedruckten internistischen Zeitschrift Ihrer Wahl.

Literatur
1.
Zurück zum Zitat Udagawa H, Akiyama H. Surgical treatment of esophageal cancer: Tokyo experience of the three-field technique. Dis Esophagus. 2001;14:110–4.CrossRefPubMed Udagawa H, Akiyama H. Surgical treatment of esophageal cancer: Tokyo experience of the three-field technique. Dis Esophagus. 2001;14:110–4.CrossRefPubMed
2.
Zurück zum Zitat Takeuchi H, Miyata H, Gotoh M, et al. A risk model for esophagectomy using data of 5354 patients included in a Japanese nationwide web-based database. Ann Surg. 2014;260:259–66.CrossRefPubMed Takeuchi H, Miyata H, Gotoh M, et al. A risk model for esophagectomy using data of 5354 patients included in a Japanese nationwide web-based database. Ann Surg. 2014;260:259–66.CrossRefPubMed
4.
Zurück zum Zitat Perry Y, Fernando HC. Three-field minimally invasive esophagectomy: current results and technique. J Thorac Cardiovasc Surg. 2012;144:S63–6.CrossRefPubMed Perry Y, Fernando HC. Three-field minimally invasive esophagectomy: current results and technique. J Thorac Cardiovasc Surg. 2012;144:S63–6.CrossRefPubMed
5.
Zurück zum Zitat Biere SS, van Berge Henegouwen MI, Maas KW, et al. Minimally invasive versus open oesophagectomy for patients with oesophageal cancer: a multicentre, open-label, randomised controlled trial. Lancet. 2012;379:1887–92.CrossRefPubMed Biere SS, van Berge Henegouwen MI, Maas KW, et al. Minimally invasive versus open oesophagectomy for patients with oesophageal cancer: a multicentre, open-label, randomised controlled trial. Lancet. 2012;379:1887–92.CrossRefPubMed
6.
Zurück zum Zitat Udagawa H, Ueno M, Kinoshita Y. Rationale for video-assisted radical esophagectomy. Gen Thorac Cardiovasc Surg. 2009;57:127–31.CrossRefPubMed Udagawa H, Ueno M, Kinoshita Y. Rationale for video-assisted radical esophagectomy. Gen Thorac Cardiovasc Surg. 2009;57:127–31.CrossRefPubMed
7.
Zurück zum Zitat Ninomiya I, Osugi H, Fujimura T, et al. Thoracoscopic esophagectomy with extended lymph node dissection in the left lateral position: technical feasibility and oncologic outcomes. Dis Esophagus. 2014;27:159–67.CrossRefPubMed Ninomiya I, Osugi H, Fujimura T, et al. Thoracoscopic esophagectomy with extended lymph node dissection in the left lateral position: technical feasibility and oncologic outcomes. Dis Esophagus. 2014;27:159–67.CrossRefPubMed
8.
Zurück zum Zitat Akiyama H. Squamous cell carcinoma of the thoracic esophagus. Surgery for Cancer of the Esophagus. Baltimore: Williams & Wilkins; 1990. p. 19–42. Akiyama H. Squamous cell carcinoma of the thoracic esophagus. Surgery for Cancer of the Esophagus. Baltimore: Williams & Wilkins; 1990. p. 19–42.
9.
Zurück zum Zitat Osugi H, Takemura M, Lee S, et al. Thoracoscopic esophagectomy for intrathoracic esophageal cancer. Ann Thorac Cardiovasc Surg. 2005;11:221–7.PubMed Osugi H, Takemura M, Lee S, et al. Thoracoscopic esophagectomy for intrathoracic esophageal cancer. Ann Thorac Cardiovasc Surg. 2005;11:221–7.PubMed
10.
Zurück zum Zitat Sasako M, McCulloch P, Kinoshita T, et al. New method to evaluate the therapeutic value of lymph node dissection for gastric cancer. Br J Surg. 1995;82:346–51.CrossRefPubMed Sasako M, McCulloch P, Kinoshita T, et al. New method to evaluate the therapeutic value of lymph node dissection for gastric cancer. Br J Surg. 1995;82:346–51.CrossRefPubMed
11.
Zurück zum Zitat International Union Against Cancer. Oesophagus. In: Sobin LH, Wittekind C, editors. TNM classification of malignant tumours. 6th ed. Hoboken: Wiley-Lis; 2002. p. 60–4. International Union Against Cancer. Oesophagus. In: Sobin LH, Wittekind C, editors. TNM classification of malignant tumours. 6th ed. Hoboken: Wiley-Lis; 2002. p. 60–4.
12.
Zurück zum Zitat International Union Against Cancer. Oesophagus including oesophagogastric junction. In: Sobin LH, Gospodarowicz MK, Wittekind C, editors. TNM classification of malignant tomours. 7th ed. Hoboken: Wiley-Blackwell; 2009. p. 66–72. International Union Against Cancer. Oesophagus including oesophagogastric junction. In: Sobin LH, Gospodarowicz MK, Wittekind C, editors. TNM classification of malignant tomours. 7th ed. Hoboken: Wiley-Blackwell; 2009. p. 66–72.
13.
Zurück zum Zitat Japan Esophageal Society. Japanese classification of esophageal cancer, tenth edition: part I. Esophagus. 2009;6:1–25.CrossRef Japan Esophageal Society. Japanese classification of esophageal cancer, tenth edition: part I. Esophagus. 2009;6:1–25.CrossRef
14.
Zurück zum Zitat Nakamura K, Kato K, Igaki H, et al. Three-arm phase III trial comparing cisplatin plus 5-FU (CF) versus docetaxel, cisplatin plus 5-FU (DCF) versus radiotherapy with CF (CF-RT) as preoperative therapy for locally advanced esophageal cancer (JCOG1109, NExT study). Jpn J Clin Oncol. 2013;43:752–5.CrossRefPubMed Nakamura K, Kato K, Igaki H, et al. Three-arm phase III trial comparing cisplatin plus 5-FU (CF) versus docetaxel, cisplatin plus 5-FU (DCF) versus radiotherapy with CF (CF-RT) as preoperative therapy for locally advanced esophageal cancer (JCOG1109, NExT study). Jpn J Clin Oncol. 2013;43:752–5.CrossRefPubMed
Metadaten
Titel
Re-evaluation of the role of thoracoscopic esophagectomy as a Japanese-style radical surgery
verfasst von
Harushi Udagawa
Masaki Ueno
Shusuke Haruta
Tsuyoshi Tanaka
Aya Mizuno
Yu Ohkura
Publikationsdatum
03.01.2017
Verlag
Springer Japan
Erschienen in
Esophagus / Ausgabe 2/2017
Print ISSN: 1612-9059
Elektronische ISSN: 1612-9067
DOI
https://doi.org/10.1007/s10388-016-0567-z

Weitere Artikel der Ausgabe 2/2017

Esophagus 2/2017 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.